key: cord-0931151-p8dlu2na authors: Sargazi, Saman; Sheervalilou, Roghayeh; Rokni, Mohsen; Shirvaliloo, Milad; Shahraki, Omolbanin; Rezaei, Nima title: The role of autophagy in controlling SARS‐CoV‐2 infection: An overview on virophagy‐mediated molecular drug targets date: 2021-04-23 journal: Cell Biol Int DOI: 10.1002/cbin.11609 sha: ec64de71403d921a2144794ec2ebd268e6a7e260 doc_id: 931151 cord_uid: p8dlu2na Autophagy‐dependent cell death is a prominent mechanism that majorly contributes to homeostasis by maintaining the turnover of organelles under stressful conditions. Several viruses, including coronaviruses (CoVs), take advantage of cellular autophagy to facilitate their own replication. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a beta‐coronavirus (β‐CoVs) that mediates its replication through a dependent or independent ATG5 pathway using specific double‐membrane vesicles that can be considered as similar to autophagosomes. With due attention to several mutations in NSP6, a nonstructural protein with a positive regulatory effect on autophagosome formation, a potential correlation between SARS‐CoV‐2 pathogenesis mechanisms and autophagy can be expected. Certain medications, albeit limited in number, have been indicated to negatively regulate autophagy flux, potentially in a way similar to the inhibitory effect of β‐CoVs on the process of autophagy. However, there is no conclusive evidence to support their direct antagonizing effect on CoVs. Off‐target accumulation of a major fraction of FDA‐approved autophagy modulating drugs may result in adverse effects. Therefore, medications that have modulatory effects on autophagy could be considered as potential lead compounds for the development of new treatments against this virus. This review discusses the role of autophagy/virophagy in controlling SARS‐CoV‐2, focusing on the potential therapeutic implications. erate their replication (Cottam et al., 2011; Kemball et al., 2010) . However, not all viruses are as elusive. In the majority of cases, autophagy restricts the replication of viruses through a specific process called "virophagy," hence, the containment of infection (Mao et al., 2019) . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen behind the novel coronavirus disease 2019 pandemic (Jabbari et al., 2020; Rokni, Ghasemi et al., 2020; Sheervalilou et al., 2020) , is a beta-coronavirus (β-CoV) (Banaei et al., 2020; Rokni, Hamblin et al., 2020) . Notably, SARS-CoV and MERS-CoV, the culprits for the severe acute respiratory syndrome coronavirus (SARS), and the Middle East respiratory syndrome (MERS) outbreaks in the past, also belong to the same category Rokni, Ahmadikia et al., 2020; Shafique et al., 2020) . With a positive-sense RNA molecule at their core (Banaei et al., 2020; Vickers, 2017) , β-CoVs mediate their replication through dependent or independent ATG5 pathway (Prentice et al., 2004) through specific double-membrane vesicles (DMVs) that are mostly similar to autophagosomes (Fung & Liu, 2019) . SARS-CoV and MERS-CoV are known to produce viral membrane-anchored papain-like protease/PLpro-TM polyprotein. An accomplice to the pathogenesis, this polyprotein accelerates the formation of autophagosomes while disrupting their maturation. As a consequence, functional autolysosomes are no longer generated to keep the infection contained (Chen et al., 2014) . However, there are several accounts on autophagy-independent pathogenesis of β-CoVs, two of which were published in 2007 and 2010 (Reggiori et al., 2010; Z. Zhao et al., 2007) . In this particular case, the replication is mediated by DMVs coated with nonlipidated microtubule-associated protein 1 light chain 3 (LC3)-I (Benvenuto et al., 2020) . Nevertheless, in 2019 it was reported that MERS-CoV infection resulted in inhibition of autophagy in the host cell (Gassen et al., 2019) . A health issue of global concern, the COVID-19 pandemic, soon became the motive for scientists to explore the mechanisms behind the peculiar effects of SARS-CoV-2 infection on patients. Several mutations in NSP6 were reported by analyzing the genetic sequence of the SARS-CoV-2 virus (Benvenuto et al., 2020) . A nonstructural protein, NSP6, has a positive regulatory effect on autophagosome formation, suggesting a potential correlation between the SARS-CoV-2 pathogenesis mechanism and autophagy (Benvenuto et al., 2020) . As of today, there are still no specific effective medications either for the prevention or treatment of COVID-19 . However, promising results have been reported following a series of attempts at repurposing the clinical application of 12 different FDA-approved drugs (COVID-19; https://www.who.int/ blueprint/priority-diseases/key-action/Table_of_therapeutics_ Appendix_17022020.pdf?ua=1). There are several medications that are thought to have modulatory effects on autophagy; however, there is no evidence indicative of their direct antagonizing effect on β-CoVs. However, they can inhibit autophagy flux in a way similar to β-CoVs (Shojaei, Suresh et al., 2020) . This updated review discusses the role of autophagy/virophagy in the pathogenesis of SARS-CoV-2, focusing mostly on the potential therapeutic implications. Figure 1 represents the process of the lung infection by SARS-CoV-2, followed by the autophagy pathway. Entry of SARS-CoV-2 into the lung cells is mainly mediated by the angiotensin-converting enzyme 2 (ACE2) receptor, meanwhile, autophagy has also been implicated in the viral replication in the cells, a process partly related to the formation of a DMV in the lung cells. 2 | AUTOPHAGY 2.1 | What is autophagy? Through the last decade, a significant amount of new findings recommended that apoptosis and necrosis are often modulated by common pathways, occurring in similar subcellular organelles and compartments (Nikoletopoulou et al., 2013) . The link between programmed cell death (PCD) pathways is a hot topic area (Kang et al., 2011; Rikiishi, 2012) . Apoptosis, as type I programmed cell death (PCDI), is triggered by intra-or extracellular stimuli via activation of a cascade of protease enzymes (Nagata, 2018) . Recently, type II programmed cell death (PCDII), or autophagy, has been recognized as a cellular "self-eating" mechanism through which cytoplasm is surrounded by a DMV (Brest et al., 2020) . Afterward, during this evolutionarily conserved process, other intracellular compartments and damaged organelles are engulfed into a double-membrane structure called phagophore that originates from cell membranes and/or cell organelles such as the endoplasmic reticulum (ER), Golgi complex, mitochondria, endosomes, and becomes an autophagosome (Salimi & Hamlyn, 2020) which ultimately fuses with the lysosome to form a degradative system, called autolysosome (Yang & Shen, 2020) . Autophagy can be classified as macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA) (Y. J. Li et al., 2017) . More recently, the term "necroptosis" was introduced to describe a condition where necrosis occurs in a regulated and programmed manner, as an alternative to accidental death, and yet is distinctive from apoptosis (Galluzzi & Kroemer, 2008) . This process, in several consecutive stages, is tightly monitored by some proteins encoded by autophagy-related genes (ATGs) (Mizushima, 2020; Yin et al., 2016) . The initiation stage is monitored by the ULK1/ATG1 complex, located downstream of rapamycin complex 1 (mTORC1). In contrast, the nucleation/expansion stage is controlled by the ATG14-Beclin-1-hVPS34/class III phosphatidylinositol 3-kinases (PI3K) complex and the two ubiquitin-like conjugation systems (ATG5-ATG12 and LC3/ATG8) as well. As explained here, ATG5 and ATG12 are conjugated and related with ATG16L1, through an ubiquitin-like conjugating system involving ATG7 as an E1-like activating enzyme and ATG10 as an E2-like conjugating enzyme needed for its function. The combination of ATG12-ATG5 acts as an E3-like enzyme, which is required for lipidation of ATG8 family proteins and their relationship to the vesicle membranes. ATG3 can also indirectly affect the formation of the ATG12-ATG5 complex as mature LC3 seems to be required for ATG12-ATG5-ATG16 conjugation, and deficiency of ATG3 in the cell indicates extremely reduced ATG12-ATG5 conjugation. In the final stage of this process, the autophagosome fuses with the lysosome to form an autolysosome for the effective degradation of the engulfed contents. In lung inflammation, deletion of ATG protein products results in autophagy-deficiency and can be studied for various applications (Bello-Perez et al., 2020; Painter et al., 2020) . Some studies demonstrated that cells with deletion of either ATG5 or ATG7 failed to impair the SARS-CoV replication rate (Yang & Shen, 2020) . Nevertheless, another studies show that β-CoVs mediate their replication through the ATG5 pathway ( Figure 2 ) (Prentice et al., 2004) . Degradation of cellular organelles or long-lived proteins through autophagy can provide an innate defense against viral pathogens. By contrast, autophagosomes can enhance infection by accelerating the formation of replicase proteins needed for viral RNA replication (Cottam et al., 2011) . For their survival, as obligate intracellular parasites, viruses can manipulate some host cell processes, such as metabolism, cellular trafficking, and host immune responses (Brest et al., 2020; Chiramel et al., 2013) . It has been well-established that autophagy has multiple immunological roles that affect infection, inflammation, and immunity. In this scenario, autophagy regulates inflammation by removing F I G U R E 1 The lung infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), followed by autophagy pathway. Entry of SARS-CoV-2 into the lung cells is mainly mediated by the angiotensin-converting enzyme 2 (ACE2) receptor, meanwhile the autophagy has also been implicated in the viral replication in the cells, a process partly related to the formation of a double-membrane vesicle in the lung cells SARGAZI ET AL. | 3 endogenous inflammasome agonists and influences the secretion of immune mediators; therefore, it interacts with the innate immune signaling pathway. Furthermore, autophagy serves a pivotal role in antigen processing by enhancing antigen presentation to T cells and thus initiates the adaptive immune response (Deretic et al., 2013) . As discussed before, autophagy safeguards the host cells against viral pathogens through different mechanisms, such as xenophagy or, more specifically, virophagy. Autophagy receptors can initiate virophagy through ubiquitin-dependent or independent manners (Khaminets et al., 2016) . It was previously demonstrated that ubiquitin-positive substrates, such as old protein aggregates, cellular organelles, and invading pathogens, are selectively targeted to lysosomes through this cell death mechanism (Fujita & Yoshimori, 2011) . In a phenomenon termed "lysophagy," the lysosome is selectively sequestered by autophagy when its membrane is disrupted (Hasegawa et al., 2015) . On the other hand, xenophagy is an evolutionarily conserved mechanism responsible for eliminating nonhost entities after the cellular invasion (Yuk et al., 2012) . Recently, it has F I G U R E 2 Autophagy involved genes. Autophagy included three protein complexes: ULK1 complex, including ULK1, ATG13, RB1CC1, and ATG101; PtdIns3K complex, including the ATG14, BECN1, PIK3R4/VPS15, PIK3C3/VPS34 and ATG16L1 complex, including ATG16L1, ATG5, and ATG12. During starvation and stress the cell is in an emergency condition, when the mTOR protein is inactivated, allowing ULK1 complex formation, then activation of the PtdIns3K complex, as the result produces the PtdIns3P-rich areas on the surface of the omegasome. WIPI proteins realize this process and recruit the ATG16L1 complex and facilitate lipidation of LC3-I to make LC3-II. Expansion of the phagophore through membrane addition sequesters some of the cytoplasm and upon closure forms the autophagosome. After formation autophagosome from phagophore, autophagosomes are fused with lysosomes to make the autolysosomes, where the cargo is digested (Bello-Perez et al., 2020) . ATG5, autophagy-related gene 5; ATG12, autophagy-related gene 12; ATG13, autophagy-related gene 13; ATG14, autophagy-related gene 14; ATG16L1, autophagy-related gene 16L1; ATG101, autophagy-related gene 101; BECN1, Beclin-1; BR1CC1, RB1 inducible coiled-coil 1; ERK, extracellular signal-regulated kinase; LC3-I, microtubule-associated proteins 1A/1B light chain 3B type I; LC3-II, microtubule-associated proteins 1A/1B light chain 3B type II; MAP2K, mitogen-activated protein kinase kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; PE, phosphatidylethanolamine; PIK3C3, phosphatidylinositol 3-kinase catalytic subunit type 3; PIK3R4, phosphatidylinositol 3-kinase regulatory subunit type 4; Ptdlns3K, phosphoinositide 3-kinase; SQSTM1, sequestosome 1; ULK1, unc-51-like kinase 1; WIPI, WD-repeat protein interacting with phosphoinositides; ZFYVE1, zinc finger FYVE domain-containing protein 1 4 | C Cell ell B Biology iology I International nternational been proposed that lysosomal damage induces AMP-protein activated kinase (AMPK) through galectin-9 while suppressing mTOR via a galectin-based system termed GALTOR (Jia et al., 2018) . In addition, some autophagy-related proteins, such as beclin-1 and LC3, are key regulators of virus-induced autophagy, and their lysosomal degradation or poly-ubiquitination reduces viral infection (Gassen et al., 2019) . Besides this, through forming autophagosomes and membranes, some viruses exploit ATGs for the creation of new virions. Afterward, these pseudoenveloped virions are released from host cells and penetrate neighboring cells (Keller et al., 2020) . There is also another theory suggesting that specific vesicles involved in ERassociated degradation, called EDEM1-containing organelles (EDE-Mosomes), are invaded by β-CoVs and used as membranes for the enclosure of newly generated virions (Reggiori et al., 2010) . Disruption of mitochondrial function and autophagy may affect the host cells' immune response during viral infections (Singh et al., 2021) . Although it has been proposed that autophagy protects host cells against viruses, there is evidence indicating that this highly conserved cellular degradative pathway might act as a double-edged sword by serving either as an antiviral defense mechanism, or instead, as a proviral process during acute virus infection (Chiramel et al., 2013) . In this regard, it has been observed that autophagy increments the genomic replication of some single-stranded RNA viruses (Fakher et al., 2020) . Autophagy can reprocess everything. Hence, it might be inexorable that future hypothesis-driven studies will delineate the function of virophagy against COVID-19, yielding the most needed therapeutic interventions (Dalibor & Danie, 2020) . Autophagy contributes to the antiviral responses as it is involved in the direct elimination of invading viruses, viral antigen presentation, suppression of excessive inflammatory reactions, and fitness of immune cells (Carmona-Gutierrez et al., 2020) . Virophagy might come into play either as a proviral or antiviral process, depending on the viral infection in the human host cell (Chiramel et al., 2013) . As the name might suggest, proviral autophagy occurs when the invading virus has adopted various mechanisms to evade autophagy and manipulate it in a way that would entirely favor the replication of the virus (Kumar et al., 2020) . This is highly important in terms of pathogenesis because certain groups of viruses, particularly β-CoVs, are known to benefit from an inappropriately induced autophagic process (Silvas et al., 2020) . SARS-CoV-2 is a highly pathogenic virus . Indeed, there is a complex interaction between the virus and the autophagic pathway. Xiong et al. (2020) reported the upregulation of cell death pathways, that is, apoptosis, autophagy, and p53 pathways in peripheral blood mononuclear cells of patients infected with SARS-CoV-2. SARS-CoV-2 also downregulates autophagy-inducing spermidine and promotes the degradation of autophagy-initiating Beclin-1 (Gassen et al., 2020) . According to Gorshkov et al. (2020) , the cytopathic effect of SARS-CoV-2 is blocked with autophagy modulators. Moreover, results from another study have supported the hypothesis that SARS-CoV-2 upregulates the expression of genes involved in inflammation processes and cytokine signaling while downregulating the genes in mitochondria/respiration and the autophagic pathway (Singh et al., 2021) . In 2015, Y. Li et al. (2015) showed that ACE2, the cellular receptor for SARS-CoV entry (also for SARS-CoV-2), could suppress cell death, emphasizing that this protein can hinder apoptosis and autophagic pathways in pulmonary systems. Gassen et al. (2020) showed that SARS-CoV-2 infection inhibits the autophagic pathway by interfering with multiple metabolic pathways. Based on this investigation, SARS-CoV-2 prevents glycolysis by reducing the activation of AMPK and mammalian target of rapamycin complex 1 (mTORC1). Upon lysophagy, the viral genome is released, and autophagy is triggered by suppressing mTOR (rapamycin) by the GALTOR complex. In the absence of stress, the mTORC1/ULK1/2 complex suppresses phagophore formation. In the case of viral infection or under stressful situations, AMPK inhibits mTORC1 and instead activates PI3K/protein kinase B (AKT1), which triggers the autophagic pathway and results in virion encapsulation. Activation of these downstream signaling pathways helps in forming autolysosomes, followed by the fusion of autophagosomes with lysosomes to degrade the viral contents (S.-W. Tang et al., 2012) . In this regard, according to Salimi and Hamlyn (2020) , impaired autophagy might be the reason for COVID-19 infection, as autophagy also plays a role in the introduction of endogenous viral antigens to CD8 + T cells by means of antigen-presenting cells (APCs). Based on another hypothesis, SARS-CoV-2 might encode virulence factors that inhibit the host cell's autophagy machinery, leading to escape lysis (Brest et al., 2020) . Considerably, almost all members of the respiratory CoVs have somehow evolved to selectively impede autophagy to promote their replication (Richards & Jackson, 2013) . Moreover, most SARS-CoV-2 proteins are evolutionarily conserved, except for the S protein. During a process termed antibodydependent enhancement of disease, antibodies against the S protein (spike) of SARS-CoV-2 trigger FC receptor-mediated uptake, which results in the infection of APCs. It has been proposed that APC infection might be responsible for dramatic T-cell depletion observed in some cases of SARS-CoV-2 infection (Fakher et al., 2020) . Chen et al. (2014) showed that the membrane-associated papain-like protease PLP2 (PLP2-TM) of CoVs functions as a SARGAZI ET AL. | 5 specific autophagy-inducing protein through interacting with LC3 and Beclin-1 (Chen et al., 2014) . In this case, PLP2-TM exacerbates autophagosome accumulation and inhibits the binding of autophagosomes to lysosomes. Brest et al. (2020) suggested that the accumulation of autophagosome like DMVs also occurs during CoVs infection, providing these viruses a membrane source for their envelope and a platform for genome replication. Generally, CoVs interact with autophagy pathway components to exploit them to replicate their genetic material and suppress the autophagic flux (Gassen et al., 2019) . Like other CoVs, the formation of pseudoenveloped vesicles during SARS-CoV-2-induced autophagy relies on ER-derived membranes (Fakher et al., 2020) . Yang and Shen (2020) proposed that endocytosis of cathepsin proteases might be an essential mediator of viral entry for several CoVs, such as SARS-CoVs, MERS-CoVs, and perhaps SARS-CoV-2. As cysteine proteases, cathepsins serve pivotal roles in protein degradation in many cellular processes, specifically autophagy (Schrezenmeier & Dörner, 2020) . Benvenuto et al. (2020) performed an evolutionary analysis of 351 available sequences of the SARS-CoV-2 genome, aiming to discover any mutations developed during the COVID-19 pandemic. They found that one synonymous mutation in nonstructural protein 6 (NSP6) significantly altered the relationship of SARS-CoV-2 with its host, explicitly concerning a decisive host antiviral defense, such as the autophagic lysosomal machinery. In light of these findings, it has been reported that NSP6 of the avian coronavirus produces autophagosomes from the ER of the host cell. This protein impedes autophagosome expansion, and therefore, prevents the delivery of viral components to lysosomes for degradation (Lippi et al., 2020) . NSP6 also appears to restrict the expansion of autophagosomes, thus, perturbing the naturally expected conveyance of viral components to degradative organelles, ultimately favoring CoV infection (Cottam et al., 2014) . On the other hand, CMA is a lysosomal pathway that accounts for the degradation of about one-third of cytosolic proteins under stressful conditions (Dice, 2007) . The heat shock protein 90 (HSP90) is a protein relevant to viral infections (Wyler et al., 2020 It is assumed that autophagy/virophagy modulation might eventually be part of the "disposal strategies" in the feisty fight against SARS-CoV-2. However, it is necessary to foster and extend robust research involving the potential function of this pathway as it concerns infectious diseases, such as CoVs (Dalibor & Danie, 2020) . Table 1 presents a list of drugs used in the treatment of COVID-19, and candidate therapeutic agents ("https://www.who.int/blueprint/ priority-diseases/key-action/Table_of_therapeutics_Appendix_ 17022020.pdf?ua=1"), with potential regulatory effects on autophagy (Shojaei, Suresh et al., 2020; Yang & Shen, 2020) . It should be noted that the greater proportion of these medications do not have any kind of direct antagonizing effects on SARS-CoVs or SARS-CoV-2, but rather, they inhibit the autophagy flux (Shojaei, Suresh et al., 2020) . In light of this knowledge, it has been theorized that these therapeutic agents can potentially work by overaccumulating in autophagosomes, which may trigger apoptosis and result in the death of cells infected by the virus (Shojaei, Koleini et al., 2020) . There is no medication to have been officially approved for selective Despite their sought-after inhibitory effects on autophagy, hydroxychloroquine (HCQ) and chloroquine (CQ) are known to have a narrow therapeutic index that results in their dose-limiting toxicity. This poses a challenge to evaluate their mechanism of action in patients with COVID-19 (Gorshkov et al., 2020) . The pharmacological induction of autophagy with rapamycin might promote the replication of SARS-CoV-2. HCQ on the other hand, can potentially counteract this effect and result in a slower replication (Brest et al., 2020) . This is a promising finding, owing to the fact that as an analog to CQ. HCQ is associated with fewer adverse effects, making it an intriguing contender for the treatment of COVID-19. (Chu et al., 2004; Que et al., 2003) 500 mg once, Twice a week, Inducing autophagosome accumulation (Zha et al., 2013) Gastrointestinal effects, headache, diabetes, hyperbilirubinemia, dizziness (Kim et al., 2015) (Continues) SARGAZI ET AL. | 7 Several drugs are capable of altering the pH of the cell surface. This can disrupt the fusion of the virus to the host cell membrane (Fakher et al., 2020) . For instance, CQ/HCQ with a dose of 400 mg per day for 5 days, affects the pH of the lysosomal membrane similarly, significantly impairing the fusion of lysosomes to autophagosomes in COVID-19 patient (Lu, 2020) . A lysosomotropic agent, CQ can also prompt autophagy-independent severe disorganization in the function of the Golgi apparatus, which is suspected the be the primary mechanism behind its inhibitory effects on autophagosome-lysosome fusion (Mauthe et al., 2018) . Several investigations have suggested the potential efficacy of CQ against coronavirus infections, which can be held true in the case of SARS-CoVs as well (Colson et al., 2020) . From a microscopic point of view, the action of CQ results in the accumulation of damaged mitochondria inside the cell as they can no longer be cleared due to the concomitant repression of mitophagy. This is a deleterious event, that along with the resulting oxidative stress might lead to renal tubular dysfunction in some cases (Festa et al., 2018) . Thus, CQ cannot be regarded as an ideal option for the autophagy-wise treatment of COVID-19, as it may cause simultaneous tissue damage when the therapeutic goal was to decelerate replication (Edelstein et al., 2020) . Corticosteroids are also capable of inhibiting autophagy through the conferring an enhanced risk for invasive aspergillosis (Kyrmizi et al., 2013; Saghazadeh & Rezaei, 2020) . Autophagy-affected mechanism Retrospective cohort COVID-19 (Deng et al., 2020) Retrospective method cohort SARS (Que et al., 2003) In vivo: MERS (Sheahan et al., 2020) In vitro: SARS (Chu et al., 2004) Ruxolitinib (Jakavi®, Jakafi®) Myelofibrosis and polycithaemia vera treatment Clinical trial COVID-19 (Cong et al., 2018) Not available Downregulating the mTORC1-RPS6KB-EIF4EBP1 pathway (Ishida et al., 2018) , Inducing accumulation of autophagosomes (Kusoglu et al., 2020) Anemia, pancytopenia (Alimam et al., 2015) Abbreviations: COVID-19, coronavirus disease 2019; CQ, chloroquine; EIF4EBP1, eukaryotic initiation factor 4E-binding protein; HCQ, hydroxychloroquine; H1N1, hemagglutinin type 1 and neuraminidase type 1 (influenza strain; aka swine flu); IFNα2a, interferon alpha-2a; LC3, microtubule-associated protein 1A/1B-light chain 3; MESR, Middle East respiratory syndrome; mTORC1, mammalian target of rapamycin; P62, mouse sequestosome-1; PEGylated, polyethylene glycol; RPS6KB, ribosomal protein S6 kinase; SARS, severe acute respiratory syndrome; SQSTM1, sequestosome 1. cytokines and chemokines. These effects, however, are negated once there is exposure to morphine. "ERA" is another combinatorial preparation that includes emtricitabine, ritonavir, and atazanavir. Similar to LAR, ERA has also been reported to be counteracted by morphine in terms of controlling the virus replication. It is speculated that the upregulation of p62/SQSTM1 caused by antiretroviral drugs and subsequent possible modulation of autophagy by these agents might be the culprit for the increased neurotoxicity witnessed in HIVinfected primary human astrocytes treated with antiretroviral agents (Rodriguez et al., 2019) . In a separate investigation, scientists explored the mechanism behind the activation of microglia through combined antiretroviral therapy (cART). They noticed that certain combinations, such as tenofovir-disoproxil-fumarate, increased the permeability of the Several other therapeutic agents such as clomipramine, hycanthone, verteporfin, and mefloquine may potentially block the pathogenic effect of SARS-CoV-2 in Vero-E6 cells. With an EC 50 value of 2-13 µM, these drugs may have the potential to be further appraised for their efficacy in the treatment of SARS-CoV-2 infection through modulation of autophagic pathways (Gorshkov et al., 2020) . A small dimeric molecule, ROC-325, is an inhibitor of autophagy, which is administrated orally. Containing core motifs of HCQ and lucanthone, this novel agent inhibits lysosomal-mediated autophagy. Compared to HCQ, ROC-325 is suggested to be ten times more potent in terms of anticancer and antiautophagic activity, the latter of which may counteract the cytopathic effects of SARS-CoV-2, with negligible inherent cytotoxicity Jones et al., 2019) . Based on the cytopathic effects assay results reported by Gorshkov et al., the counter-autophagic activity of ROC-325 was significantly correlated with repression of the cytopathic effects of SARS-CoV-2, as measured by LC3B spot counts (Gorshkov et al., 2020) . MERS-CoV multiplication is thought to cause the Beclin-1 levels to fall and block the lysosome-autophagosome fusion. A key regulatory factor of autophagy, Beclin-1, is poly-ubiquitinated and subsequently degraded by S-phase kinase-associated protein 2 (SKP2). The activity of SKP2, on the other hand, is controlled through phosphorylation in a hetero-complex involving AKT1, PHLPP, FKBP51, and Beclin-1. Genetic inactivity or external inhibition of SKP2 results in reduced ubiquitination of Beclin-1 and slowing down its degradation while promoting the autophagic flux. SKP2 inhibition not only accelerates autophagy but also slows MERS-CoV replication by approximately 28,000-fold. The link between SKP2 and Beclin-1 makes the molecule a potential target for antiviral drugs. Thus, agents promoting autophagy through SKP2 could be considered potential candidates for the autophagy-mediated treatment of COVID-19 (Lydie, 2020) . Interferon alfa-2b or IFN-α2b is a triggering factor for the accumu- The most effective therapy for HIV infection to date, highly active antiretroviral therapy, consists primarily of HIV protease inhibitors (PI). Lopinavir is one such PI that, combined with ritonavir or even alone, can induce an ER stress response, inhibit cell differentiation, and initiate apoptosis in adipocytes. This type of HIV PI-induced ER stress is highly likely to be associated with the inhibition of autophagy, especially in adipocytes that is very well recorded with lopinavir/ritonavir. Thus, there might be potential therapeutic targets within the autophagy signaling pathways that could be used to treat PI-induced metabolic adverse effects in patients with HIV infection (Zha et al., 2013) . Multiple clinical trials are underway to examine any possible relations between lopinavir/ritonavir and COVID-19 more precisely (NCT04255017). In this clinical trial, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of SARS-CoV-2 pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir, and lopinavir/ritonavir in the treatment of SARS-CoV-2 viral pneumonia, and to explore effective antiviral drugs for new coronavirus (Ning, 2020) . Ruxolitinib is a Janus kinase inhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors SARGAZI ET AL. According to an in vitro study on macrophages, a considerable disruption in autophagic degradation is thought to be imminent upon the prolonged exposure of these phagocyting cells to exogenous recombinant human IL-6. This was confirmed by the elevated levels of LC3B and p62 measured in both primary and transformed macrophages. A humanized monoclonal antibody with anti-IL-6R activity (Rokni, Hamblin et al., 2020) , tocilizumab (TCZ) was recently indicated to reverse the impairment of autophagic degradation and mitigate p62 accumulation in macrophages in a paracrine manner (Hsu et al., 2021) . This particular type of antibody has also been proposed as an effective candidate therapeutic option for the treatment of COVID-19 (Delorme-Axford & Klionsky, 2020). The rationale behind this proposal lies within the COVID-19-associated induction of IL-6 in the form of a cytokine storm mediated by T cells and monocytes. Thus, selective targeting of the excess IL-6 by an agent, TCZ in this scenario, is speculated to alleviate this inflammatory storm. Besides this, an improvement in body temperature and respiratory function was reported in patients treated with TCZ. Therefore, we suggest that TCZ is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality (Fu et al., 2020 Nonetheless, successful conclusion of the ongoing third phase of this clinical investigation is warranted to safely recommend administration of TCZ (Perrone et al., 2020) . Overall, despite the available evidence, if limited, regarding the efficacy and potential adverse effects of the therapeutic agents reviewed in this paper, further investigations are needed to illustrate the common molecular mechanisms involved both in the pathogenesis of SARS-CoV-2 and pharmacodynamics of these drugs, and the potential interactions between them despite, to give us a full picture on the most optimal approach. Clinical application of nanoparticles is associated with a promising novel approach called nanomedicine, which is chiefly concerned with precise targeting of active sites while avoiding the offtarget accumulation of the therapeutic agent. Thanks to this groundbreaking advancement, it can soon be possible to closely monitor the interaction between any given drug and the target cell and restrict the final therapeutic outcome only to the target area as a direct consequence of several unique properties found exclusively in nanoparticles, such as high targeting capacity, large surface-area-tovolume ratio, substantial bioavailability, and capacity to be readily modified with ligands, whose receptors are found within the target sites. In this regard, nanotechnology can be a game-changing asset in the ongoing fight against COVID-19 by paving the road for developing novel therapies that can selectively hinder the replication of the virus in target cells. The authors declare that there are no conflict of interests. Autophagy-virus interplay: from cell biology to human disease The use of JAK inhibitors for low-risk myelofibrosis Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study Obstetrics and neonatal outcomes in pregnant women with COVID-19: A systematic review Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-coV replication in BALB/c mice Canonical and noncanonical autophagy as potential targets for COVID-19 Evolutionary analysis of SARS-CoV-2: How mutation of non-structural protein 6 (NSP6) could affect viral autophagy Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war Disruption of autophagic degradation with ROC-325 antagonizes renal cell carcinoma pathogenesis Drain the lysosome: Development of the novel orally available autophagy inhibitor ROC-325 Digesting the crisis Coronavirus membrane-associated papain-like proteases induce autophagy through interacting with Beclin1 to negatively regulate antiviral innate immunity The world health organization international clinical trials registered organization registered platform The world health organization international clinical trials registered organization registered platform The world health organization international clinical trials registered organization registered platform The world health organization international clinical trials registered organization registered platform The world health organization international clinical trials registered organization registered platform The world health organization international clinical trials registered organization registered platform The world health organization international clinical trials registered organization registered platform The world health organization international clinical trials registered organization registered platform Divergent roles of autophagy in virus infection Autophagy and cancer Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Glucocorticoid therapy for COVID-19 critically ill patients with severe acute respiratory failure Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate Coronavirus NSP6 restricts autophagosome expansion Autophagy/virophagy: A "disposal strategy" to combat COVID-19 Highlights in the fight against COVID-19: Does autophagy play a role in SARS-CoV-2 infection? Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study Autophagy in infection, inflammation and immunity Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture Chaperone-mediated autophagy Autophagy and viruses: Adversaries or allies Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19 The role of autophagy in respiratory complications of COVID-19 Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney Why tocilizumab could be an effective treatment for severe COVID-19? Ubiquitination-mediated autophagy against invading bacteria Human coronavirus: Host-pathogen interaction Necroptosis: A specialized pathway of programmed necrosis Caspases connect cell-death signaling to organismal homeostasis Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators Autophagy as a cell death and tumor suppressor mechanism The end and after: How dying cells impact the living organism Selective autophagy: Lysophagy. Methods Retinopathy associated with high-dose interferon alfa-2b therapy Systemic lupus erythematosus is associated with impaired autophagic degradation via interleukin-6 in macrophages Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2 COVID-19: A chimera of two pandemics Galectins control mTOR in response to endomembrane damage Moving beyond hydroxychloroquine: The novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies Chikungunya virus-induced autophagy delays caspase-dependent cell death The Beclin 1 network regulates autophagy and apoptosis Autophagy and microbial pathogenesis Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in pancreatic acinar cells in vivo In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine Ubiquitin-dependent and independent signals in selective autophagy immunopathogenesis and immunotherapeutics of COVID-19; an overview Comparison of antiretroviral regimens: adverse effects and tolerability failure that cause regimen switching Strategies employed by viruses to manipulate autophagy. Autophagy in health and disease Ruxolitinib regulates the autophagy machinery in multiple myeloma cells Corticosteroids block autophagy protein recruitment in Aspergillus fumigatus phagosomes via targeting dectin-1/Syk kinase signaling Long-term therapy in COPD: Any evidence of adverse effect on bone? Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways Autophagy and multidrug resistance in cancer SARS-CoV-2: At the crossroad between aging and neurodegeneration COVID-19: Transmission, prevention, and potential therapeutic opportunities SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences Efficacy and safety of hydroxychloroquine for treatment of pneumonia caused by 2019-nCoV (HC-nCoV) Tocilizumab treatment in COVID-19: A single center experience SKiPping coronavirus infection: Inhibiting the E3 ligase SKP2 provides a new way to induce autophagy and reduce MERScoronavirus infection Autophagy and viral infection Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion The ATG conjugation systems in autophagy Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19 Apoptosis and clearance of apoptotic cells Crosstalk between apoptosis, necrosis and autophagy A prospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia Full Text View -ClinicalTrials Role of autophagy in lung inflammation Tocilizumab for patients with COVID-19 pneumonia: The single-arm TOCIVID-19 prospective trial The interferons: 50 years after their discovery, there is much more to learn Coronavirus replication complex formation utilizes components of cellular autophagy Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study Coronaviruses hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication How positive-strand RNA viruses benefit from autophagosome maturation Novel insights into the interplay between apoptosis and autophagy Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: Diagnostic role of inflammatory indications in determining the severity of illness Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS Cytokines and COVID-19: friends or foes? Autophagy in measles virus infection Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids COVID-19 and crosstalk between the hallmarks of aging Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. Pathogens Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication Network analysis and transcriptome profiling identify autophagic and mitochondrial dysfunctions in SARS-CoV-2 infection Drug repositioning suggests a role for the heat shock protein 90 Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient Impact of cellular autophagy on viruses: Insights from hepatitis B virus and human retroviruses Substitution of tenofovir/emtricitabine for hepatitis B immune globulin prevents recurrence of hepatitis B after liver transplantation Antiretroviralmediated microglial activation involves dysregulated autophagy and lysosomal dysfunction Animal communication: When i'm calling you, will you answer too? Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019 nCoV) in vitro Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro HIV-1 and HIV-2 infections induce autophagy in Jurkat and CD4+ T cells The SARS-CoV-2 outbreak: What we know Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients Functional interaction of heat shock protein 90 and Beclin 1 modulates toll-like receptor-mediated autophagy Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19 Autophagy: machinery and regulation Autophagy and bacterial infectious diseases HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes Interferon-alpha-2b induces autophagy in hepatocellular carcinoma cells through Beclin1 pathway Coronavirus replication does not require the autophagy gene ATG5 Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. Scientific Reports, 11, 6725. How to cite this article